Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
MRVI vs ARVN: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
ARVN Captures Overall Composite Edge (52.9 HOLD vs 49.0 HOLD), While MRVI Leads 4–2 on Growth & Valuation Pillars
ARVN Overall Winner
6-Pillar Tally: MRVI 4 – 2 ARVN
Matrix Metrics: MRVI 3 – 7 ARVN
As of Nov 16, 2026, Arvinas, Inc (ARVN) captures the overall head-to-head institutional edge over Maravai LifeSciences Holdings, Inc. (MRVI) on higher Unified Composite conviction (52.9/100 HOLD vs. 49.0/100 HOLD) after splitting the core matrix 7–3 (led by Valuation Multiples, Profitability & Quality), while MRVI wins 4–2 across the 6-pillar growth and valuation breakdown. MRVI trades at $7.45 (N/M Forward P/E, -24.2% operating margin) versus ARVN at $6.74 (17.9x Forward P/E, -10.1% operating margin).
- Growth vs. Quality Trade-Off: ARVN earns the overall head-to-head edge with a stronger Unified Composite Score (52.9/100 HOLD vs. MRVI 49.0/100 HOLD) and 1.40β · 66% Vol risk profile, whereas MRVI leads top-line expansion (+10.1% YoY revenue growth, N/M PEG, and 4 of 6 institutional pillars) for higher-beta growth mandates.
- Technical & Structure Timing Caution: MRVI trades in a Neutral technical trend (BREAKOUT options phase, RSI 49.1); meanwhile ARVN is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 41.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Executive Snapshot Side-by-Side Composite Ratings & Technical Regime
Ask Alpha AI About MRVI vs ARVN
MRVI
Maravai LifeSciences Holdings, Inc. Class A Common Stock
$7.45
-1.19% 1D
Market Cap
$2.0B
TTM Revenue
$213M
Forward P/E
N/M
Beta / 30D Vol
1.61β · 83% Vol
Unified Composite Score
49.0
HOLD
Tech 37.0
Fund 48.0
Flow 67.0
Mom 64.0
Weinstein Technical Phase
Neutral · Hold
ARVN
Head-to-Head Winner
Arvinas, Inc
$6.74
-1.17% 1D
Market Cap
$449.9M
TTM Revenue
$275M
Forward P/E
17.9x
Beta / 30D Vol
1.40β · 66% Vol
Unified Composite Score
52.9
HOLD
Tech 54.0
Fund 59.0
Flow 71.0
Mom 54.0
Weinstein Technical Phase
Markdown · Sell / avoid
6-Pillar Scorecard Institutional Category Breakdown (MRVI 4 – 2 ARVN)
1. Valuation Multiples
ARVN
Forward P/E
N/M
17.9x
Trailing P/E
N/M
17.9x
PEG Ratio
N/M
N/M
EV / Revenue
9.9x
1.3x
2. Growth & Scale
MRVI
Revenue Growth (YoY)
+10.1%
-98.8%
Earnings Growth (YoY)
-32.7%
+0.0%
TTM Revenue (USD)
$213M
$275M
Market Cap
$2.0B
$449.9M
3. Profitability & Quality
ARVN
Gross Margin
39.9%
96.7%
Operating Margin
-24.2%
-10.1%
Net Profit Margin
-30.8%
-3.5%
Return on Equity (ROE)
-29.8%
-1.8%
4. Balance Sheet & Cash Flow
MRVI
Cash Generation (TTM)
-$13M
-$160M
Cash Flow Margin
-5.9%
-58.0%
Net Cash / Leverage
$103M Net Debt (0.90x D/E)
$81M Net Cash
Dividend Yield
None (0.00%)
None (0.00%)
5. Options & Positioning
MRVI
Options Structure Phase
BREAKOUT
BREAKDOWN
Current IV / %ile
111.8% (17th %ile)
108.7% (25th %ile)
Put/Call OI Skew
0.01x (Call-Skewed)
0.01x (Call-Skewed)
OBV Trend / Tech Phase
DISTRIBUTION · Neutral
DISTRIBUTION · Markdown
6. R&D & Supply-Chain Moat
MRVI
OpEx & R&D Intensity
64.1% of Rev ($137M)
N/A
90D R&D Disclosures
0 papers
0 papers
Competitive Moat
Cyclical / Execution-Driven Positioning
Cyclical / Execution-Driven Positioning
Supply-Chain Role
Biotechnology Operator
Biotechnology Operator
Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table
Core Matrix Wins: MRVI (3) vs ARVN (7)| Institutional Metric | MRVI | ARVN | Criterion | Row Edge |
|---|---|---|---|---|
| Market Capitalization | $2.0B | $449.9M | MRVI | |
| Trailing P/E Ratio | N/M | 17.9x | ARVN | |
| Forward P/E Ratio | N/M | 17.9x | ARVN | |
| Revenue Growth (YoY) | +10.1% | -98.8% | MRVI | |
| Operating Margin (TTM) | -24.2% | -10.1% | ARVN | |
| Net Profit Margin | -30.8% | -3.5% | ARVN | |
| Return on Equity (ROE) | -29.8% | -1.8% | ARVN | |
| 52-Week Range Position | 70% ($3–$9) | 5% ($6–$15) | MRVI | |
| Beta / 30D Volatility | 1.61β · 83% Vol | 1.40β · 66% Vol | ARVN | |
| Unified Institutional Score | 49.0 / 100 (HOLD) | 52.9 / 100 (HOLD) | ARVN | |
| Trailing 12M Revenue (USD) | $213M | $275M | Scale | |
| Gross Profit Margin (TTM) | 39.9% | 96.7% | Quality | |
| PEG Ratio & EV / Revenue | N/M PEG · 9.9x EV/Rev | N/M PEG · 1.3x EV/Rev | Valuation | |
| Cash Flow & Balance Sheet | -$13M ($103M Net Debt (0.90x D/E)) | -$160M ($81M Net Cash) | Solvency |
Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)
1M Horizon
MRVI +13.02 pp
3M Horizon
MRVI +57.0 pp
6M Horizon
MRVI +105.83 pp
1Y Horizon
MRVI +162.63 pp
Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | MRVI Revenue | ARVN Revenue | MRVI Op. Margin | ARVN Op. Margin | Margin Leader |
|---|---|---|---|---|---|
| FY2018 | N/A | $10M | N/A | -306.3% | ARVN |
| FY2019 | $140M | $20M | 16.8% | -281.4% | MRVI |
| FY2020 | $280M | $20M | 42.2% | -554.1% | MRVI |
| FY2021 | $800M | $50M | 69.4% | -403.4% | MRVI |
| FY2022 | $880M | $130M | 65.0% | -200.3% | MRVI |
| FY2023 | $290M | $80M | -11.0% | -511.5% | MRVI |
| FY2024 | $260M | $260M | -90.9% | -95.0% | MRVI |
| FY2025 | $190M | $260M | -115.9% | -45.1% | ARVN |
Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor
Live Options Phase Tracker
MRVI
BREAKOUT
Current IV
111.8%
IV Percentile
17th %ile
Put/Call OI Skew
0.01x (Call-Skewed)
IV Regime
Compressed (<25th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
BULLISH
OBV Flow
DISTRIBUTION
Exact MRVI Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
ARVN
BREAKDOWN
Current IV
108.7%
IV Percentile
25th %ile
Put/Call OI Skew
0.01x (Call-Skewed)
IV Regime
Balanced (25th–60th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
BULLISH
OBV Flow
DISTRIBUTION
Exact ARVN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity
Corporate R&D & Foundry Leaderboard
MRVI Moat Profile
Cyclical / Execution-Driven Positioning
Biotechnology Operator
OpEx & R&D Reinvestment
64.1% of Rev ($137M)
90D Engineering Disclosures
0 Published
ARVN Moat Profile
Cyclical / Execution-Driven Positioning
Biotechnology Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
Investor FAQ MRVI vs ARVN Key Questions & Quantitative Answers
As of Nov 16, 2026, Arvinas, Inc (ARVN) captures the overall head-to-head institutional edge over Maravai LifeSciences Holdings, Inc. (MRVI) on higher Unified Composite conviction (52.9/100 HOLD vs. 49.0/100 HOLD) after splitting the core matrix 7–3 (led by Valuation Multiples, Profitability & Quality), while MRVI wins 4–2 across the 6-pillar growth and valuation breakdown. MRVI trades at $7.45 (N/M Forward P/E, -24.2% operating margin) versus ARVN at $6.74 (17.9x Forward P/E, -10.1% operating margin). Growth vs. Quality Trade-Off: ARVN earns the overall head-to-head edge with a stronger Unified Composite Score (52.9/100 HOLD vs. MRVI 49.0/100 HOLD) and 1.40β · 66% Vol risk profile, whereas MRVI leads top-line expansion (+10.1% YoY revenue growth, N/M PEG, and 4 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: MRVI trades in a Neutral technical trend (BREAKOUT options phase, RSI 49.1); meanwhile ARVN is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 41.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
MRVI leads the Growth & Scale pillar: MRVI posts +10.1% YoY revenue growth and -32.7% YoY earnings growth on $213M TTM revenue (39.9% gross margin, -24.2% operating margin), compared with ARVN at -98.8% YoY revenue growth and +0.0% YoY earnings growth on $275M TTM revenue (96.7% gross margin, -10.1% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), MRVI cumulative revenue shifted +35.7% while ARVN shifted +2500.0%. In operating R&D and SG&A reinvestment, MRVI deploys 64.1% of Rev ($137M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for ARVN.
ARVN screens cheaper on headline valuation multiples. MRVI trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 9.9x EV/Revenue (-5.9% FCF margin), whereas ARVN trades at 17.9x Forward P/E, 17.9x Trailing P/E, N/M PEG, and 1.3x EV/Revenue (-58.0% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against MRVI (-29.8% ROE) versus ARVN (-1.8% ROE) capital efficiency.
In options market volatility and institutional positioning, MRVI carries 111.8% implied volatility (17th %ile, Compressed (<25th %ile)), a 0.01x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKOUT options structure phase (1.61β · 83% Vol realized risk). By comparison, ARVN carries 108.7% implied volatility (25th %ile, Balanced (25th–60th %ile)), a 0.01x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.40β · 66% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Launch Custom Ticker Comparison →
ARVN vs MRVI · Reverse Pair
MRVI vs SHC
· Sector Peer
MRVI vs CERT
· Sector Peer
ARVN vs KYMR
· Sector Peer
ARVN vs DNLI
· Sector Peer
ARVN vs RCUS
· Sector Peer
INTC vs AMD
· x86 & Data Center CPU
NVDA vs AMD
· AI Accelerators
TSM vs ASML
· Foundry & Lithography
MSFT vs GOOGL
· Hyperscale Cloud & AI
AAPL vs META
· Consumer Ecosystem